DarioHealth Corp. (DRIO)
USD 0.65
(-9.08%)
USD 0.65
(-9.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -56.18 Million USD | 1.32% |
| 2022 | -56.81 Million USD | 25.73% |
| 2021 | -76.49 Million USD | -155.81% |
| 2020 | -29.9 Million USD | -68.9% |
| 2019 | -17.7 Million USD | -0.1% |
| 2018 | -17.68 Million USD | -22.67% |
| 2017 | -14.41 Million USD | -29.89% |
| 2016 | -11.1 Million USD | -44.21% |
| 2015 | -7.69 Million USD | 32.22% |
| 2014 | -11.35 Million USD | 16.25% |
| 2013 | -13.56 Million USD | -241.24% |
| 2012 | -3.97 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -16.07 Million USD | 6.9% |
| 2024 Q1 | -17.26 Million USD | -22.54% |
| 2023 FY | -56.06 Million USD | 1.32% |
| 2023 Q3 | -15.54 Million USD | -10.88% |
| 2023 Q2 | -14.02 Million USD | -12.99% |
| 2023 Q4 | -14.08 Million USD | 9.39% |
| 2023 Q1 | -12.4 Million USD | -37.71% |
| 2022 Q4 | -9.01 Million USD | 38.17% |
| 2022 Q3 | -14.57 Million USD | 16.03% |
| 2022 Q2 | -17.35 Million USD | -9.34% |
| 2022 Q1 | -15.87 Million USD | 26.74% |
| 2022 FY | -56.81 Million USD | 25.73% |
| 2021 FY | -76.49 Million USD | -155.81% |
| 2021 Q1 | -14.32 Million USD | -58.06% |
| 2021 Q2 | -18 Million USD | -25.66% |
| 2021 Q3 | -22.49 Million USD | -24.97% |
| 2021 Q4 | -21.66 Million USD | 3.71% |
| 2020 FY | -29.9 Million USD | -68.9% |
| 2020 Q1 | -10.11 Million USD | -141.9% |
| 2020 Q2 | -4.12 Million USD | 59.23% |
| 2020 Q4 | -9.06 Million USD | -37.29% |
| 2020 Q3 | -6.6 Million USD | -60.13% |
| 2019 Q2 | -5.36 Million USD | 0.02% |
| 2019 Q4 | -4.18 Million USD | -49.37% |
| 2019 FY | -17.7 Million USD | -0.1% |
| 2019 Q1 | -5.36 Million USD | -4.03% |
| 2019 Q3 | -2.79 Million USD | 47.8% |
| 2018 Q4 | -5.15 Million USD | -31.14% |
| 2018 Q2 | -5.72 Million USD | -99.2% |
| 2018 Q1 | -2.87 Million USD | 7.76% |
| 2018 FY | -17.68 Million USD | -22.67% |
| 2018 Q3 | -3.93 Million USD | 31.36% |
| 2017 FY | -14.41 Million USD | -29.89% |
| 2017 Q4 | -3.11 Million USD | -4.46% |
| 2017 Q3 | -2.98 Million USD | 27.54% |
| 2017 Q2 | -4.11 Million USD | 2.07% |
| 2017 Q1 | -4.2 Million USD | -9.68% |
| 2016 FY | -11.1 Million USD | -44.21% |
| 2016 Q1 | -1.92 Million USD | -3.28% |
| 2016 Q2 | -2.62 Million USD | -36.4% |
| 2016 Q3 | -2.72 Million USD | -3.74% |
| 2016 Q4 | -3.83 Million USD | -40.9% |
| 2015 Q4 | -1.86 Million USD | 26.89% |
| 2015 Q2 | -1.51 Million USD | 14.91% |
| 2015 Q1 | -1.77 Million USD | 31.12% |
| 2015 FY | -7.69 Million USD | 32.22% |
| 2015 Q3 | -2.54 Million USD | -68.45% |
| 2014 Q3 | -2.5 Million USD | 30.42% |
| 2014 Q4 | -2.58 Million USD | -2.91% |
| 2014 Q2 | -3.6 Million USD | -35.04% |
| 2014 Q1 | -2.66 Million USD | 26.94% |
| 2014 FY | -11.35 Million USD | 16.25% |
| 2013 Q1 | -3.07 Million USD | -93.46% |
| 2013 Q2 | -3.59 Million USD | -16.9% |
| 2013 Q4 | -3.65 Million USD | -12.75% |
| 2013 Q3 | -3.23 Million USD | 9.94% |
| 2013 FY | -13.56 Million USD | -241.24% |
| 2012 Q2 | -866.34 Thousand USD | -75.11% |
| 2012 Q4 | -1.59 Million USD | -55.4% |
| 2012 FY | -3.97 Million USD | 0.0% |
| 2012 Q1 | -494.74 Thousand USD | 0.0% |
| 2012 Q3 | -1.02 Million USD | -18.11% |
| 2001 Q2 | -18 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -215.24 Million USD | 73.895% |
| Prenetics Global Limited | -52.51 Million USD | -6.999% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1192.89% |
| CareDx, Inc | -101.9 Million USD | 44.859% |
| Exact Sciences Corporation | -215.01 Million USD | 73.867% |
| Exagen Inc. | -22.83 Million USD | -146.044% |
| Inotiv, Inc. | -81.46 Million USD | 31.023% |
| Guardant Health, Inc. | -564.72 Million USD | 90.05% |
| Biodesix, Inc. | -41.34 Million USD | -35.913% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -2066.458% |
| Precipio, Inc. | -7.62 Million USD | -637.388% |
| iSpecimen Inc. | -11.16 Million USD | -403.064% |
| Natera, Inc. | -446.24 Million USD | 87.408% |
| Aspira Women's Health Inc. | -18.85 Million USD | -198.053% |
| Standard BioTools Inc. | -76.6 Million USD | 26.646% |
| 23andMe Holding Co. | -321.35 Million USD | 82.515% |
| Castle Biosciences, Inc. | -67.97 Million USD | 17.341% |
| Personalis, Inc. | -109.93 Million USD | 48.889% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 42.286% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -412.987% |
| OpGen, Inc. | -15.68 Million USD | -258.155% |
| T2 Biosystems, Inc. | -49.66 Million USD | -13.138% |
| Myriad Genetics, Inc. | -123.7 Million USD | 54.576% |
| ICON Public Limited Company | 956.15 Million USD | 105.877% |
| NeoGenomics, Inc. | -107.73 Million USD | 47.846% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1192.89% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 105.121% |
| RadNet, Inc. | 98.69 Million USD | 156.931% |
| MDxHealth SA | -27.32 Million USD | -105.617% |
| Psychemedics Corporation | -2.92 Million USD | -1823.622% |
| Illumina, Inc. | -1.06 Billion USD | 94.744% |
| Check-Cap Ltd. | -19.28 Million USD | -191.331% |
| Twist Bioscience Corporation | -220.83 Million USD | 74.556% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 22.706% |
| Sera Prognostics, Inc. | -39.82 Million USD | -41.104% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -434.079% |
| OPKO Health, Inc. | -157.02 Million USD | 64.216% |
| Medpace Holdings, Inc. | 336.82 Million USD | 116.682% |
| Neogen Corporation | 58.66 Million USD | 195.783% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -446.417% |
| Prenetics Global Limited | -52.51 Million USD | -6.999% |
| Mainz Biomed B.V. | -26.64 Million USD | -110.883% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -604.721% |
| Trinity Biotech plc | -27.04 Million USD | -107.761% |
| Neuronetics, Inc. | -30.55 Million USD | -83.901% |
| Sotera Health Company | 276.69 Million USD | 120.307% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -604.721% |